🟢 Neurosense Therapeutics is trading 6.81% up in pre-market following continued after-hours strength despite no confirmed company-specific catalyst

Neurosense Therapeutics is trading now 6.81% up at $0.41 after closing at $0.38 on August 18, 2026, following continued after-hours strength without a confirmed company-specific announcement.

• The rebound follows a 11.57% regular-session decline.
• Recent coverage instead highlights existing financing, Nasdaq-compliance concerns, and PrimeC development updates, none of which directly explain the August 19 pre-market move.
• Broader U.S. indexes are only modestly higher, making market direction unlikely to explain the move.